COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that in a February 1st meeting its Medical Advisory Board (MAB) provided recommendations for proceeding with the clinical development of the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute Oxycyte™. Synthetic Blood also announced the addition of Derek Ralph Brinster, M.D., and Christine Stowe Rinder, M.D., to its MAB, bringing total membership to 13.
